Ascent Therapeutics: There's Still Money in Discovery Platforms

It's a common perception that venture investors have turned their backs-or at least hidden their pocketbooks-from big think platform-based biotechs in search of early stage funding. But a quick look at the large A rounds raised in recent years suggests that sentiment isn't exactly true. Start-ups with promising technologies capable of generating multiple products across a wide swath of therapeutic areas are still gaining funding despite the dearth of capital. One example: Ascent Therapeutics.

It’s a common perception that venture investors have turned their backs—or at least hidden their pocketbooks—from big think platform-based biotechs in search of early stage funding. But a quick look at the large A rounds raised in recent years suggests that sentiment isn’t exactly true. Even as the pool of available capital shrinks and despite the gloomy exit environment, start-ups with promising technologies capable of generating multiple products across a wide swath of therapeutic areas are still gaining funding.

One company that recently emerged from stealth mode: Anchor Therapeutics Inc., which aims to develop drug candidates that interfere...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.